Hyera Kim1,2, Seung Tae Kim1, Kwai Han Yoo3, Jung Yong Hong1, Young Suk Park1, Ho Yeong Lim1, Joon Oh Park4. 1. Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. 2. Division of Hematology-Oncology, Department of Internal Medicine, Keimyung University Dongsan Hospital, Daegu, Republic of Korea. 3. Division of Hematology and Oncology, Department of Internal Medicine, Gachon University Gil Medical Center, Gachon University College of Medicine, Incheon, Republic of Korea. 4. Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea; oncopark@skku.edu.
Abstract
BACKGROUND/AIM: Biliary tract cancer (BTC) has a poor prognosis due to its highly invasive and metastatic potential. Ataxia-telangiectasia mutated (ATM) is a key regulator of DNA damage response and an emerging therapeutic target; however, the association between the expression of ATM and the prognosis in advanced BTC is unknown. We aimed to identify the relationship between ATM expression, clinicopathological characteristics, and survival outcomes in patients with advanced BTC. PATIENTS AND METHODS: We analyzed 113 patients with advanced BTC who received first-line gemcitabine and platinum. RESULTS: The tumor location was intrahepatic cholangiocarcinoma (IH-CCC) in 43 patients, extrahepatic cholangiocarcinoma (EH-CCC) in 49, and gallbladder (GB) cancer in 21 patients. Fifty-four patients (47.8%) exhibited loss of ATM protein expression. The overall response rate (ORR) of ATM loss and intact ATM was 13.3% and 19.6%, respectively. In a subgroup analysis, EH-CCC patients with ATM loss tended to have improved PFS after platinum-based chemotherapy compared to those with intact ATM (7.9 vs. 6.2 months, respectively; p=0.050). CONCLUSION: We demonstrated that ATM loss could be a prognostic marker after platinum-based chemotherapy in patients with advanced EH-CCC. Copyright
BACKGROUND/AIM: Biliary tract cancer (BTC) has a poor prognosis due to its highly invasive and metastatic potential. Ataxia-telangiectasia mutated (ATM) is a key regulator of DNA damage response and an emerging therapeutic target; however, the association between the expression of ATM and the prognosis in advanced BTC is unknown. We aimed to identify the relationship between ATM expression, clinicopathological characteristics, and survival outcomes in patients with advanced BTC. PATIENTS AND METHODS: We analyzed 113 patients with advanced BTC who received first-line gemcitabine and platinum. RESULTS: The tumor location was intrahepatic cholangiocarcinoma (IH-CCC) in 43 patients, extrahepatic cholangiocarcinoma (EH-CCC) in 49, and gallbladder (GB) cancer in 21 patients. Fifty-four patients (47.8%) exhibited loss of ATM protein expression. The overall response rate (ORR) of ATM loss and intact ATM was 13.3% and 19.6%, respectively. In a subgroup analysis, EH-CCC patients with ATM loss tended to have improved PFS after platinum-based chemotherapy compared to those with intact ATM (7.9 vs. 6.2 months, respectively; p=0.050). CONCLUSION: We demonstrated that ATM loss could be a prognostic marker after platinum-based chemotherapy in patients with advanced EH-CCC. Copyright
Authors: Haeryoung Kim; Burcu Saka; Spencer Knight; Michael Borges; Erica Childs; Alison Klein; Christopher Wolfgang; Joseph Herman; Volkan N Adsay; Ralph H Hruban; Michael Goggins Journal: Clin Cancer Res Date: 2014-01-31 Impact factor: 12.531
Authors: P M L H Vencken; M Kriege; D Hoogwerf; S Beugelink; M E L van der Burg; M J Hooning; E M Berns; A Jager; M Collée; C W Burger; C Seynaeve Journal: Ann Oncol Date: 2011-01-12 Impact factor: 32.976
Authors: Tomasz Byrski; Rebecca Dent; Pawel Blecharz; Malgorzata Foszczynska-Kloda; Jacek Gronwald; Tomasz Huzarski; Cezary Cybulski; Elzbieta Marczyk; Robert Chrzan; Andrea Eisen; Jan Lubinski; Steven A Narod Journal: Breast Cancer Res Date: 2012-07-20 Impact factor: 6.466